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doi:10.1
1352Objective: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to
20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the
tenting forces and improve the repair results.
Methods: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary
muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients
were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular
ejection fraction was 42%  6%. The mean tenting area and coaptation depth was 3.2  0.6 cm2 and 1.3 
0.2 cm, respectively. The study endpoints were early mortality and clinical and echocardiographic outcomes,
freedom from cardiac-related deaths, and cardiac-related events.
Results: In-hospital death occurred in 5 patients (4.5%), without a statistically significant difference between
the 2 groups (P ¼ .72). The 5-year freedom from cardiac-related deaths and cardiac-related events in the PPM
relocation group versus the RA group was 90.9%  1.8% versus 89%  1.6% (P ¼ .82) and 83%  2.1%
versus 65.4%  1.2% (P<.001), respectively. Recurrent MR equal to or greater than moderate occurred in
2 (3.7%) and 6 (11.5%) patients in the PPM relocation group and RA group (P ¼ .01), respectively. Moreover,
we found statistically significant differences for the postoperativemean tenting area and coaptation depth in both
groups (P<.001).
Conclusions: PPM relocation in conjunction to mitral annuloplasty is an easy and safe method and can be per-
formed without an increase in-hospital mortality. This technique reduced the tenting area and coaptation depth
compared with isolated RA, leading to improvement in the incidence of recurrent MR. The PPM group of pa-
tients experienced fewer cardiac-related events. (J Thorac Cardiovasc Surg 2012;143:1352-5)Currently, there is general agreement about the efficacy
of the surgical treatment for patients with severe ischemic
mitral valve regurgitation (IMR) but the best surgical
approach is still in conflict.1 Many investigators advocated
mitral valve restrictive annuloplasty (RA), meanwhile
others have suggested mitral valve replacement.2-6
Investigators supporting a conservative approach believe
that conservation of the continuity between the valve and
left ventricle lead to better long-term results and a reverse
in left ventricular (LV) remodeling.3,7 In contrast, many
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The Journal of Thoracic and Cardiovascular Surprosthesis with subvalvular apparatus conservation to
avoid recurrent MR. The incidence of recurrent MR after
isolated RA was 5% to 20% in several reports.8,9 There
are many opinions in favor of adding subvalvular
procedures to mitral annuloplasty (MA) to reduce the
tenting forces and improve the long-term repair results.10
The aim of our study was to compare the results of both ap-
proaches, papillary muscle (PPM) relocation and MAwith
isolated RA.
MATERIALS AND METHODS
Patients
From March 2003 to May 2010, 55 patients with severe IMR (effective
regurgitant orifice area,20 mm2) who underwent PPM relocation in con-
junction with MA and coronary artery bypass grafting (CABG) were en-
rolled. The patients were matched 1:1 with patients who underwent
isolated RA and CABG (using the propensity score) to obtain 2 groups
with similar preoperative characteristics. The variables chosen for the
matching process were the number of diseased vessels, LV ejection frac-
tion, type of myocardial infarction (MI), New York Heart Association
(NYHA) functional class, congestive heart failure, atrial fibrillation, coap-
tation depth, tenting area, and interpapillary distance. All patients with
IMR had restrictive systolic leaflet motion (Carpentier’s type IIIb) and an-
nular dilation.MRwas defined as ischemic when caused by coronary artery
disease in patients who had a previous MI, 2 weeks or more before hospital
admission for CABG and exhibited normal valve apparatus anatomy. The
exclusion criteria were PPM infarction causing its rupture or elongation,gery c June 2012
TABLE 1. Baseline, intraoperative characteristics, outcomes, and
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Variable
PPM relocation
plus MA RA
P
value
Mean age (y) 62  12 62  8 .91
Male gender 32 (58) 34 (61.8) .82
Diabetes mellitus 15 (27.2) 14 (25.5) .81
Chronic obstructive pulmonary
disease
6 (11) 5 (9) .75
Hypertension 28 (51) 31 (56.3) .53Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
IMR ¼ ischemic mitral valve regurgitation
LV ¼ left ventricular
MA ¼ mitral (valve) annuloplasty
MI ¼ myocardial infarction
NYHA ¼ New York Heart Association
PPM ¼ papillary muscle
RA ¼ restrictive annuloplastyRenal failure* 5 (9) 7 (12.7) .62
Unstable angina 14 (25.5) 13 (23.6) .81
Congestive heart failure 16 (29) 15 (27.2) .78
Atrial fibrillation 3 (5.4) 4 (7.2) .36
NYHA class>II 17 (31) 16 (29) .77
Side of previous MI
Anterior 13 (23.6) 13 (23.6) 1.0
Inferior 38 (69) 36 (65.4) .68
Both 6 (11) 8 (14.5) .55
Echocardiographic data
Mean tenting area 3.2  0.9 3.2  0.2 .81
Mean coaptation depth 1.3  0.1 1.3  0.3 .76
LVEDD (mm) 58  8 58  2 .97
LVESD (mm) 48  1 48  4 .81
Mean LVEF (%) 42  8 42  5 .89
Perioperative data
CPB time (min) 115  30 108  35 .08
Aortic crossclamp time (min) 86  18 84  15 .12
Grafts/patient 2.9  0.4 2.8  0.6 .36
Bleeding 3 (5.4) 2 (3.6) .76
Renal failure (dialysis) 2 (3.6) 2 (3.6) 1.0
LCOS 1 (1.8) 2 (3.6) .51
Sepsis 0 1 (1.8) —
In-hospital mortality 2 (3.6) 3 (5.4) .72
Follow-up data
NYHA class>II 2 (3.7) 3 (5.7) .71
Hospital readmission for CHF 2 (3.7) 7 (13.4) .01
Recurrent MR moderate or
greater
2 (3.7) 6 (11.5) .02
Mean tenting area (cm2) 1.2  0.3 2.3  0.4 <.001
Mean coaptation depth 0.6  0.2 1  0.2 <.001
LVEDD (mm) 50  7 54  8 .02
LVESD (mm) 40  8 44  5 .02
Mean LVEF (%) 46  5 45  4 .21
Data presented as mean SD or number (%).CPB,Cardiopulmonary bypass; LCOS,
low cardiac output syndrome; LVEDD, left ventricular end-diastolic diameter; LVEF,
left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MA,
mitral annuloplasty;MI,myocardial infarction;MR,mitral regurgitation;NYHA,New
York Heart Association; PPM, papillary muscle; RA, restrictive annuloplasty. *Serum
creatinine>1.5 mg/dL.
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valve lesions (rheumatic, infective, degenerative), and surgical restoration
of the left ventricle. The institutional review board of our university ap-
proved the study. The authorization waived patient consent. The baseline
patient characteristics are listed in Table 1.
Study Endpoints
The study endpoints were as follows: the incidence of early mortality
and outcomes, freedom from late cardiac-related deaths and cardiac-
related events, NYHA functional class, and reverse LV remodeling. Car-
diac events were defined as the occurrence of at least 1 of the following:
cardiac death, MI, congestive heart failure, redo on mitral valve, revascu-
larization (CABG or percutaneous intervention), new-onset atrial fibrilla-
tion, worsening in NYHA functional class, recurrent MR equal to or
greater than moderate, and hospital re-admission.
Surgical Technique
All patients underwent conventional multivessel CABG through a full
midline sternotomy under normothermic cardiopulmonary bypass with
intermittent antegrade cold-blood cardioplegia. For every patient, the by-
pass grafts used were the internal thoracic artery and the long saphenous
vein. All distal anastomoses were performed during a single aortic cross-
clamping. The proximal graft anastomoses were performed during side
clamping.
MA was performed using a Carpentier-Edwards physio ring (Edwards
Life Sciences, Irving, Calif) or the Saddle Rigid ring (St. Jude Medical,
Minneapolis, Minn). The ring size was determined according to the sur-
face of the anterior leaflet. Regarding the ‘‘restrictive annuloplasty’’
group, we used a ring with a surface 2 sizes less than anterior leaflet sur-
face. In the ‘‘relocation PPM’’ group, we did not use a smaller size but
the normal size. We believe that in patients who undergo PPM relocation,
the use of a ring according to the anterior leaflet surface should be effec-
tive without having to use undersizing. The rings were inserted using
deep horizontal U sutures and Ticron 2-0 suture (Syneture, Norwalk,
Conn).
PPM relocation was performed using a CV-4 Gore-Tex suture (W. L.
Gore and Associates, Flagstaff, Ariz) placed first at the head of each PPM
and subsequently through the ipsilateral mitral annulus, during an
arrested heart, in accordance with the technique described by Kron and
colleagues.10 We relocated both PPMs to minimize mitral valve tenting
(Figure 1). Usually, 1 head of the anterior PPM was relocated. However,
among the 3 heads of the posterior PPM, we relocated the anterior and
posterior ones. It is very important to relocate both heads of the posterior
PMs, because from the anterior PM arises the chordae for the anterior
leaflet responsible for the seagull sign and respective tenting and from
the posterior PM arises the chordae to the posterior leaflet (P2 and P3
scallops).
All patients underwent postoperative transesophageal echocardiogra-
phy of the left ventricle and valve function. Mitral valve repair wasThe Journal of Thoracic and Carconsidered successful if no or trivial residual MR was present and the co-
aptation surface was about 0.8 cm.
Clinical and Echocardiographic Follow-up
All patients were followed up by our cardiologists at 6-month inter-
vals. The pre- and postoperative clinical status was determined accord-
ing to the criteria of the NYHA functional class and the Canadian
Cardiovascular Society for heart failure symptoms and angina,diovascular Surgery c Volume 143, Number 6 1353
FIGURE 1. Schematic representation of papillary muscle (PPM)
relocation.
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were 100% complete. The follow-up period started September 2010
and ended November 2010. The mean follow-up period was 32 
12 months.
Statistical Analysis
The numeric values are presented as themean standard deviation. The
frequency ratios are given as percentages. Continuous variables were com-
pared between the 2 groups using Student’s unpaired t test. The frequency
ratios between the 2 groups were compared using the c2 test. Stepwise lo-
gistic regression analysis was used to realize a model to calculate the pro-
pensity score. The LVend-diastolic diameter, LVend-systolic diameter, and
LV ejection fraction were analyzed using the paired t test and Wilcoxon
signed rank test. Variables were put into a Cox regression model. Where
appropriate, hazard ratios were computed with the 95% confidence inter-
vals. The actuarial survival and other time-related events were analyzed us-
ing the Kaplan-Meier method. The log-rank test was used to compare the
statistical significance level. P< .05 was considered statistically signifi-
cant. The Statistical Package for Social Sciences statistical software
(SPSS, Chicago, Ill) was used.FIGURE 2. Kaplan-Meier log-rank test used to compare (A) cardia
1354 The Journal of Thoracic and Cardiovascular SurRESULTS
No statistically significant difference was found between
the 2 groups for the preoperative demographics or clinical
and echocardiographic characteristics owing to the match-
ing process. No statistically significant difference was found
between the 2 groups for the intraoperative data (Table 1).
Early Outcomes
In-hospital deaths for the entire population occurred in 5
patients (4.5%), without a statistically significant differ-
ence between the 2 groups (P¼ .72). Two (3.6%) and three
(5.4%) patients died in the PPM relocation group and iso-
lated RA group, respectively. The causes of in-hospital
death were low cardiac output in 3 patients, sepsis in 1,
and multiorgan failure in 1. Intra-aortic balloon pump im-
plantation was necessary to treat postoperative cardiogenic
shock in 3 patients (2.7%).
Late Mortality and Outcomes
The overall 5-year freedom from cardiac-related death
rate in the PPM relocation group and the isolated RA group
was 90.9%  1.8% and 89%  1.6% (P ¼ .82), respec-
tively (Figure 2, A). Late cardiac deaths occurred in 6 pa-
tients (5.7%). The causes of late death were congestive
heart failure in 3 patients, arrhythmias in 2, and sudden
death in 1. The following independent variables for late
mortality in the entire population were found on Cox anal-
ysis: LV ejection fraction of 30% or less (hazard ratio, 9;
95% confidence interval, 2.1–36; P ¼ .004) and NYHA
class of III or greater (hazard ratio, 5.6; 95% confidence in-
terval, 1.6–42; P ¼ .007).
The 5-year freedom from cardiac-related event rate in the
PPM relocation group and isolated RA group was 83% 
2.1% and 65.4%  1.2% (P < .001), respectively
(Figure 2, B).
At follow-up, the NYHA functional class improved from
2.6  1.1 to 1.4  0.3 (P ¼ .021) in the PPM relocation
group and 2.5  0.9 to 1.6  0.4 (P ¼ .026) in the isolated
RA group.c-related deaths and (B) cardiac-related events among 2 groups.
gery c June 2012
Fattouch et al Acquired Cardiovascular Disease
A
C
DEchocardiographic Data at Follow-Up
Recurrent MR equal to or greater than moderate occurred
in 2 (3.7%) and 6 (11.5%) patients in the PPM relocation
group and RA group, respectively (P ¼ .01).
Reversal in LV remodeling measured by a change in the
LVend-diastolic diameter and LVend-systolic diameter was
significantly observed in both group compared with base-
line, but the PPM relocation approach promoted a signifi-
cant reversal in LV remodeling compared with the
isolated RA approach (Table 1).
The postoperative mean tenting area was 1.2  0.3 cm2
and 2.3  0.4 cm2 for the PPM relocation and RA groups,
respectively (P<.001). The postoperative mean coaptation
depth was 0.6  0.2 cm and 1.1  0.2 cm in the PPM relo-
cation and RA groups, respectively (P<.001).
DISCUSSION
Although the surgical treatment of severe IMR in patients
presenting forCABG is recommended by theAmericanCol-
lege of Cardiology/American Heart Association guide-
lines,1 the best surgical approach is still being debated.
Several clinical studies have provided only limited informa-
tion about the dilemma to repair or replace themitral valve in
patients with severe IMR.4,6 This conflicting decision is
mainly affected by the lack of prospective studies and,
often, by the comparison of clinical outcomes for both
procedures in dissimilar patient groups. Evidence is
awaited from a current randomized study (evaluation of
outcomes following mitral valve repair/replacement in
severe chronic ischemic mitral regurgitation; available
from: www.ctsurgerynet.org/SMRAbstract.html). Investi-
gators favoring a conservative approach believe that
undersizing with MA improves the early and late clinical
outcomes and leads to reversal in LV remodeling.2,3,5,7
However, the incidence of recurrent MR in patients who
have undergone isolated RA has been up to 20% to
30%.8,9 In contrast, replacement of the mitral valve by
a bioprosthesis with conservation of the subvalvular
apparatus eliminates the incidence of MR recurrence but
leads to the risk of prosthesis valve-related events.
Currently, RA is still associated with poor outcomes in
many series, probably for different reasons. First, wide het-
erogeneity exists in published reports regarding the type of
prosthetic ring (complete, band, rigid, flexible, pericar-
dium) used by surgeons for MA that inevitably leads to dif-
ferent results. Second, RA was performed in all patients
with IMR, regardless of the degree of LV dysfunction and
dilation and the severity of mitral valve tenting and PPM
displacement. Thus, surgeons routinely perform RA as
a unique surgical solution for a complex LV disease.
Recently, several investigators proposed different surgi-
cal techniques (posterior LVwall plication, PPM relocation,The Journal of Thoracic and CarLV reconstruction, second chordae cutting, and so forth) to
add to MA to improve the long-term repair results. In the
present series, we report our experience with PPM reloca-
tion. This technique was first introduced by Kron and col-
leagues,10 and we believe is easy and reproducible. In our
series, PPM relocation was performed with low early and
late mortality. However, the patients who underwent PPM
relocation plus MA experienced fewer late cardiac-related
events than those who underwent isolated RA (P<.001).
Moreover, the incidence of recurrent MR was greater in
the RA group.
LV reverse remodeling has previously been observed af-
ter restrictive MA.3,7 In the present series, we found that
PPM relocation reduce the LV end-diastolic diameter
(P ¼ .02) and LV end-systolic diameter (P ¼ .02) more
than did RA. However, it is not clear whether PPM reloca-
tion can have a favorable effect on LV reverse remodeling
compared with isolated RA. We suggest that PPM reloca-
tion can reduce the tenting area and coaptation depth better
and probably avoid additional displacement of the PPMs.
In conclusion, PPM relocation is a safe method. This
technique reduce the tenting area and coaptation depth com-
pared with isolated RA, leading to a low incidence of recur-
rent MR. Moreover, we found that PPM relocation
promotes better reverse LV remodeling compared with iso-
lated RA.
References
1. Bonow RO, Carabello BA, Chatterjee K, et al. American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. ACC/AHA 2006
Guidelines for the Management of Patients With Valvular Heart Disease. JACC.
2006;48:1-148.
2. Bolling SF, Deeb GM, Brunsting LA, Bach DS. Early outcome of mitral valve
reconstruction in patients with end-stage cardiomyopathy. J Thorac Cardiovasc
Surg. 1995;109:676-82.
3. Fattouch K, Guccione F, Sampognaro R, et al. Efficacy of adding mitral valve re-
strictive annuloplasty to CABG in patients with moderate ischemic mitral valve
regurgitation: a randomised trial. J Thorac Cardiovasc Surg. 2009;138:278-85.
4. Gillinov AM, Wierup PN, Blackstone EH, et al. Is repair preferable to replace-
ment for ischemic mitral regurgitation? J Thorac Cardiovasc Surg. 2001;122:
1125-41.
5. Adams DH, Chen RH, Byrne JG, et al. Improving outcomes in patients with mod-
erate ischemic mitral regurgitation undergoing combined CABG and mitral an-
nuloplasty. Circulation. 2000;102(Suppl II):II-462.
6. Vassileva CM, Boley T, Markwell S, Hazelrigg S. Meta-analysis of short-term
and long-term survival following repair versus replacement for ischemic mitral
regurgitation. Eur J Cardiothoracic Surg. 2011;39:295-303.
7. Bax JJ, Braun J, Somer ST, et al. Restrictive annuloplasty and coronary revascu-
larization in ischemic mitral regurgitation results in reverse left ventricular re-
modeling. Circulation. 2004;110(Suppl II):II-103-8.
8. Kuwahara E, Otsuji Y, Iguro Y, et al. Mechanism of recurrent/persistent ische-
mic/functional mitral regurgitation in chronic phase after surgical annuloplasty:
importance of augmented posterior leaflet tethering. Circulation. 2006;114:
I-529-34.
9. Mihalijevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve annuloplasty
combined with revascularization in patients with functional ischemic mitral re-
gurgitation. JACC. 2007;49:2191-201.
10. Kron IL, Randall Green G, Cope JT. Surgical relocation of the posterior papillary
muscle in chronic ischemic mitral regurgitation. Ann Thorac Surg. 2002;74:
600-1.diovascular Surgery c Volume 143, Number 6 1355
